tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks Momentum IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Pro Newsletters
Smart Value
New
Research Tools
Trending StocksCompare StocksCompare ETFsMost Visited Websites
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News WireArrivedEquityMultiple
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Smart Value
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA

MRUS Stock Latest News

Buy Rating on Merus: Promising Potential of Petosemtamab in Combination with PD-1 Therapy for Head and Neck Cancer
RatingsBuy Rating on Merus: Promising Potential of Petosemtamab in Combination with PD-1 Therapy for Head and Neck Cancer
4d ago
MRUS
Merus price target lowered to $70 from $73 at BofA
PremiumThe Fly
Merus price target lowered to $70 from $73 at BofA
15d ago
MRUS
Merus N.V. Reports 2024 Earnings and Clinical Progress
PremiumCompany Announcements
Merus N.V. Reports 2024 Earnings and Clinical Progress
20d ago
MRUS
Merus’s Promising Clinical Developments and Strategic Advancements Reinforce Buy Rating with $67 Target
PremiumRatings
Merus’s Promising Clinical Developments and Strategic Advancements Reinforce Buy Rating with $67 Target
22d ago
MRUS
Promising Outlook for Merus’ Petosemtamab: Buy Rating Reaffirmed Amidst Encouraging Clinical Progress
PremiumRatings
Promising Outlook for Merus’ Petosemtamab: Buy Rating Reaffirmed Amidst Encouraging Clinical Progress
22d ago
MRUS
Merus Receives Buy Rating from Andrew Berens Due to Promising Pipeline and Financial Stability
PremiumRatingsMerus Receives Buy Rating from Andrew Berens Due to Promising Pipeline and Financial Stability
22d ago
MRUS
Merus’s Strategic Advancements and Clinical Progress Justify Buy Rating
Premium
Ratings
Merus’s Strategic Advancements and Clinical Progress Justify Buy Rating
25d ago
MRUS
Merus: Buy Rating Affirmed on Promising Clinical Progress and Strong Financial Position
Premium
Ratings
Merus: Buy Rating Affirmed on Promising Clinical Progress and Strong Financial Position
25d ago
MRUS
Merus’s Promising Clinical Advances and Breakthrough Therapy Designation Justify Buy Rating
PremiumRatings
Merus’s Promising Clinical Advances and Breakthrough Therapy Designation Justify Buy Rating
25d ago
MRUS
Promising Developments in Merus’s Pipeline: Petosemtamab’s Potential in HNSCC and mCRC
PremiumRatings
Promising Developments in Merus’s Pipeline: Petosemtamab’s Potential in HNSCC and mCRC
25d ago
MRUS
Merus’s Promising Clinical Developments and Regulatory Progress Justify Buy Rating
PremiumRatings
Merus’s Promising Clinical Developments and Regulatory Progress Justify Buy Rating
26d ago
MRUS
Merus reports FY24 EPS ($3.35), consensus ($3.72)
PremiumThe Fly
Merus reports FY24 EPS ($3.35), consensus ($3.72)
26d ago
MRUS
Merus’s Breakthrough in HNSCC: Buy Rating Backed by FDA Support and Promising Trial Data
PremiumRatingsMerus’s Breakthrough in HNSCC: Buy Rating Backed by FDA Support and Promising Trial Data
1M ago
MRUS
Merus’s Breakthrough Therapy Designation and Strong Financials Justify Buy Rating
Premium
Ratings
Merus’s Breakthrough Therapy Designation and Strong Financials Justify Buy Rating
1M ago
MRUS
Merus’ petosemtamab granted Breakthrough Therapy designation by FDA
Premium
The Fly
Merus’ petosemtamab granted Breakthrough Therapy designation by FDA
1M ago
MRUS
Target downgraded, Cisco upgraded: Wall Street’s top analyst calls
PremiumThe Fly
Target downgraded, Cisco upgraded: Wall Street’s top analyst calls
1M ago
M
AS
Analyst Recommends Buy for Merus Based on Promising Petosemtamab Developments and Revenue Potential
PremiumRatings
Analyst Recommends Buy for Merus Based on Promising Petosemtamab Developments and Revenue Potential
1M ago
MRUS
Merus initiated with an Overweight at Piper Sandler
PremiumThe Fly
Merus initiated with an Overweight at Piper Sandler
1M ago
MRUS
Roblox downgraded, Pinterest upgraded: Wall Street’s top analyst calls
PremiumThe Fly
Roblox downgraded, Pinterest upgraded: Wall Street’s top analyst calls
2M ago
PH
ELF
Merus initiated with an Overweight at Wells Fargo
PremiumThe FlyMerus initiated with an Overweight at Wells Fargo
2M ago
MRUS
Biohaven enters multi-target collaboration with Merus
Premium
The Fly
Biohaven enters multi-target collaboration with Merus
2M ago
BHVN
MRUS
Biohaven, Merus enter research pact and license agreement to develop three ADCs
Premium
The Fly
Biohaven, Merus enter research pact and license agreement to develop three ADCs
2M ago
BHVN
MRUS

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >